Researchers present studies suggesting that GLP-1 drugs may reduce cancer risk, improve survival, and increase responses to treatments in cancer patients. However, experts caution that trials are needed to confirm any anti-cancer benefits.
A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer.
More than two dozen studies presented over the past few days at the American Society of Clinical Oncology meeting in Chicago found that patients taking the drugs showed lower risks of developing cancer and disease progression, better survival, and improved responses to some treatments, compared with people who were not taking the GLP-1s. The studies included analyses of clinical records and real-world databases tracking patients taking Novo Nordisk's Wegovy or Ozempic, Eli Lilly's Zepbound or Mounjaro, or older GLP-1 treatments.
The studies were not designed to show how or why GLP-1 use might affect cancer treatment. But researchers believe by reducing inflammation, regulating insulin signaling and possibly engaging directly with tumor biology, they may contribute to a protective effect in cancer patients. Chronic inflammation is a fundamental biological pathway involved in the development and progression of many cancers, said Dr Elizabeth Susan McDonald of the University of Pennsylvania.
McDonald on Tuesday reported on a study of 110,000 women, showing those who took GLP-1 medications were up to 35 per cent less likely to develop breast cancer than those who did not. While obesity itself is a known risk factor for certain cancers, the anti-inflammatory effects of GLP-1s will likely prove to have a role in cancer prevention, McDonald said.
GLP-1 drugs include semaglutide, the active ingredient in Wegovy, Ozempic and Rybelsus; tirzepatide, sold as Mounjaro and Zepbound, as well as Lilly's Trulicity, or dulaglutide, and Novo's older liraglutide, sold as Saxenda and Victoza. Some of the strongest signals of benefit came from a study of more than 12,000 patients that showed GLP-1 use was associated with markedly lower odds of cancers advancing to metastatic disease, particularly in lung, breast, colorectal and liver cancers.
People with those cancers who took liraglutide, pramlintide, dulaglutide, tirzepatide, lixisenatide, or semaglutide were 38 per cent to 50 per cent less likely to see the disease spread than people who took drugs from a different class of diabetes medicines known as gliptins. Reduced cancer incidence, longer survival, and fewer metastases were also seen with GLP-1 use in patients with endometrial, bladder and prostate cancers, as well as in those with small intestine neoplasms and blood cancers, multiple studies found.
A separate analysis of patients treated at US community oncology practices found GLP-1 use was associated with significantly better overall survival across six tumour types. Researchers also reported that cancer patients receiving immunotherapies such as Merck's Keytruda and Bristol Myers Squibb's Opdivo or Yervoy appeared to fare better when they were taking GLP-1 drugs, suggesting a possible interaction with the immune system.
GLP-1 users with type 2 diabetes and stage 3 kidney disease had substantially lower mortality and lower rates of several malignancies, particularly lung, colorectal, and hepatocellular cancers, than non-users. While GLP-1 medications carry a warning regarding a possible association with a type of thyroid cancer based on rodent studies, researchers say the recent findings point to a potential beneficial class effect across tumor types, rather than benefits confined to a small subset of cancers.
The drugs, originally designed to treat diabetes and found to promote weight loss, have also shown benefits for heart risks, sleep apnoea and alcohol and substance abuse. These drugs have never been just glucose-lowering agents, Dr Marcin Chwistek of the Fox Chase Cancer Center in Philadelphia said at an ASCO press briefing. Researchers cautioned that nearly all of the data presented were from observational studies, raising the risk of confounding factors.
Patients prescribed GLP-1 drugs may differ in important ways, including overall health, access to care and concurrent treatments, that could influence outcomes. While the various studies tried to account for those differences, none can prove the drugs improve cancer outcomes. Experts said trials in which GLP-1s are added to standard treatment in some cancer patients but not others are needed to establish clear anti-cancer benefits. Some trials are already being planned
Please follow us on Google to support usGLP-1 Drugs Cancer Prevention Weight Loss Diabetes Immunotherapies Metastatic Disease Overall Survival Type 2 Diabetes Stage 3 Kidney Disease
Singapore Latest News, Singapore Headlines
Similar News: You can also read news stories similar to this one that we have collected from other news sources.
Malaysia's social media account ban for under-16s kicks in on Jun 1, but questions remainThe Malaysian Communications and Multimedia Commission (MCMC) had previously announced the social media ban on May 22, which sought to reduce youths’ exposure to harmful content on digital platforms.
Read more »
Youth can be radicalised in a matter of days with AI, Shanmugam warnsFor some youth, it may just take a matter of days for them to get radicalised from extremist content online, said Coordinating Minister for National Security K Shanmugam on Tuesday (June 2).
Read more »
Two US scientists charged with smuggling deactivated mpox virus into the countryTwo researchers from a US government laboratory face charges for bringing vials of deactivated mpox virus from Africa without proper authorization and lying to authorities. The incident occurred at Detroit Metropolitan Airport after a trip to the Republic of Congo. Investigators found the virus in their possession despite denials. The scientists, virologists who have worked extensively on mpox, areexpected to appear in federal court. The National Institutes of Health stated they are cooperating with law enforcement.
Read more »
Massive Russian Attack Kills 22 People Across UkraineRussian forces launch hundreds of drones and dozens of missiles against Ukrainian cities, killing at least 22 civilians and wounding 138 others.
Read more »
Ebola Outbreak in DR Congo Shows Signs of Hope Amid Ongoing ChallengesThe Ebola outbreak in eastern DR Congo is spreading across 24 health zones, with contact tracing challenges in Ituri province. However, a sharp drop in suspected cases led to the reopening of the airport at the outbreak's epicenter. The World Food Programme highlights the role of food assistance in containing the virus.
Read more »
Commentary: Google’s AI shift is causing a collective freak-outGoogle’s AI evolution is taking the company into uncharted waters, though that may be less of a problem for parent company Alphabet than for advertisers, says Parmy Olson for Bloomberg Opinion.
Read more »